NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Key Stats

• Today's Range: $1.52 to $1.61
• 50-Day Range: $0.91 to $1.63
• 52-Week Range: $0.51 to $1.63
• Volume: 139,188 shs
• Average Volume: 252,028 shs
• Market Capitalization: $20.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

NeuroSense Therapeutics Stock Analysis - MarketRank™

NeuroSense Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 660th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeuroSense Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

NeuroSense Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroSense Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroSense Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.99% of the float of NeuroSense Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

NeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroSense Therapeutics has recently decreased by 18.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroSense Therapeutics does not currently pay a dividend.

Dividend Growth

NeuroSense Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.99% of the float of NeuroSense Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

NeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroSense Therapeutics has recently decreased by 18.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NRSN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.04% of the stock of NeuroSense Therapeutics is held by institutions.

NRSN Stock Analysis - Frequently Asked Questions

How have NRSN shares performed this year?

NeuroSense Therapeutics' stock was trading at $1.20 on January 1st, 2025. Since then, NRSN shares have increased by 31.6% and is now trading at $1.5790.
View the best growth stocks for 2025 here.

How were NeuroSense Therapeutics' earnings last quarter?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) announced its quarterly earnings data on Monday, April, 7th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06.

When did NeuroSense Therapeutics IPO?

NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroSense Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE).

Company Calendar

• Last Earnings: 4/07/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 6/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRSN
• CIK: 1875091
• Web: www.neurosense-tx.com
• Phone: 972-9799-6183
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +821.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,280,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -590.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.14) per share
• Price / Book: -10.86

Miscellaneous

• Outstanding Shares: 13,666,000
• Free Float: 9,922,000
• Market Cap: $20.77 million
• Optionable: Not Optionable
• Beta: 1.36